* [2014-2017]: FP7 Project Paincage
Genomnia is partner in the FP7 Research Project Paincage. The objectives of the project are:
  • To understand the cognitive emotional and behavioral components of pain;
  • To identify, develop and validate new specific therapeutic targets for Neuropathic Pain and Osteoarthritis,
  • To identify neuronal and glial circuitries and processes modulating nociception and endogenous analgesia;
  • To develop a pipeline of second generation NGF-system-based compounds, for an improved control of Neuropathic Pain and Osteoarthritis;
  • To identify new markers from human samples for patient stratification;
  • To improve safety profile of pharmacological approaches for Neuropathic Pain and Osteoarthritis, currently undergoing clinical testing and targeting the NGF system
* [2012-2015]: FP7 Project Radiant
Genomnia is partner in the bioinformatic research project RADIANT (Rapid Development and Distribution of Statistical Tools for High-Throughput Sequencing Data).
* [2012-2015]: NetLips Project

Genomnia is partner of the industrial research project "Lombardy Network for iPS (NetLiPS)" together with the following Institutes located on the Milan territory:

This project aims at developing the first prototype at national scale of a service platform able to certify, preserve, trace and distribute at global level pluripotent iPS cell lines for the screening, development and validation of patient-specific pharmaceuticals.

* [June 2015]: the profile of transcripts and microRNAs in glioblastoma tissues reveals molecular pathways shared between the tumours and the surrounding areas and reveals differences between the short term and long term survivors.

A scientific paper published on the Oncotarget journal contains the results of a collaborative study on glioblastoma, one of the most common and deadly brain tumours. This study investigates in an integrative manner transcriptomic data from long term or short term survivor patients, suggesting a number of markers potentially involved with the growth and aggressivity of the tumour. The NGS technologies involved were SAGe and microRNA analysis.

* [December 2014]: The NGS profile of microRNAs in rhabdomyosarcoma reveals a down-regulation of the members of the miR-378 family

A scientific paper published on the BMC Cancer journal reports the results of a microRNA massive sequencing on rhabdomyosarcoma samples, an highly malignant tumour which constitutes around half of the sarcoma cases in the soft tissues of children. This study has been conducted in collaboration with different departments of the University La Sapienza in Rome and partly financed by Fondazione Procaccini. It has shown for the first time the potential role of miR-378a-3p as possible oncosoppressor gene in rhabdomyosarcoma, underlining also the over representation of other members of the miR-378 family in this tumour.

* [July 2014]: full exome sequencing and analysis to investigate the anomalies of sex determination in humans

A scientific paper published on the Human Molecular Genetics Journal reports the results of an investigation conducted with the Laboratory of Human Genetics Development of Institut Pasteur, Paris. Sequencing and analysis of full exome results conducted in Genomnia brought to the identification of a new mutation in the FOG2 gene, responsibale of a disorder of sex determination in man (DSD).

* [March 2014]: introduction to the analysis of non-coding RNAs in neurodegenerative diseases

A review has been published on the journal Frontiers in Cellular Neuroscience, following a collaboration with a laboratory of the Hebrew University in Jerusalem, which illustrates the analytical methods used in Genomnia to analyze NGS datasets from whole transcriptome, with some 'systemic' applications which are specifically applied to neurodegenerative diseases.

* [March 2014]: coding and non-coding RNAs in the leukocytes in patients with Parkinson disease

A bioinformatic analysis of SOLiD RNA sequencing technology has been published on the PLoS Computational Biology journal. Authors are a group from the Hebrew University of Jerusalem and Genomnia. In this work we evidentiate significant dynamics of the RNAs, coding and non-coding (lincRNAs) in lymphocytes of PD patients subjected to therapeutical treatment. The possibility of retrieving in the transcriptome of circulating blood cells variations of mRNA and ncRNA levles which happened in the SNC suggests interesting possibilities at diagnostic-applicative level.

* [December 2013]: epigenetics and cardiac hypertrophy

A paper on the PNAS journal which reports ChIP-seq sequencing experiments and part of the related analyses conducted in Genomnia reveals significant correlations between epigenetic 'signatures' and cardiac hypertrophy.